Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

BACKGROUND: Sunitinib (VEGFR/PDGFR inhibitor) and everolimus (mTOR inhibitor) are both approved for advanced renal cell carcinoma (RCC) as first-line and second-line therapy, respectively. In the clinics, sunitinib treatment is limited by the emergence of acquired resistance, leading to a switch to...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, C D, Tijeras-Raballand, A, Serova, M, Sebbagh, S, Slimane, K, Faivre, S, de Gramont, A, Raymond, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453618/
https://www.ncbi.nlm.nih.gov/pubmed/25422908
http://dx.doi.org/10.1038/bjc.2014.578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453618/
https://www.ncbi.nlm.nih.gov/pubmed/25422908
http://dx.doi.org/10.1038/bjc.2014.578

Ejemplares similares